https://www.selleckchem.com/products/azd6738.html
is safe and effective in reducing relapse rate in patients with high-risk acute leukemia. The low-dose repetitive administration DLI strategy reduced the risk of DLI-mediated GVHD, while the prolonged repeated administration helped in preventing relapse, possibly by inducing a sustained and prolonged immunological pressure on residual leukemic cells. This novel strategy deserves testing in larger cohort of patients with high-risk acute leukemia. Prolonged-up to three years-low-dose pro-DLI administered every two months is safe and effec
Gefällt mir
Kommentar
Teilen
